These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 17173370

  • 1. Metabolites and safety: What are the concerns, and how should we address them?
    Smith DA, Obach RS.
    Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
    [Abstract] [Full Text] [Related]

  • 2. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA, Obach RS.
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [Abstract] [Full Text] [Related]

  • 3. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
    Smith DA, Obach RS.
    Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
    [Abstract] [Full Text] [Related]

  • 4. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG, Unger SE.
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [Abstract] [Full Text] [Related]

  • 5. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials.
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [Abstract] [Full Text] [Related]

  • 6. Metabolites in safety testing.
    Robison TW, Jacobs A.
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A regulatory perspective on issues and approaches in characterizing human metabolites.
    Davis-Bruno KL, Atrakchi A.
    Chem Res Toxicol; 2006 Dec; 19(12):1561-3. PubMed ID: 17173368
    [Abstract] [Full Text] [Related]

  • 9. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW, Frederick CB, Sistare FD, DeGeorge JJ.
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [Abstract] [Full Text] [Related]

  • 10. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T, Lin JH, Baillie TA.
    Toxicol Appl Pharmacol; 2006 Dec 01; 217(2):143-52. PubMed ID: 17055014
    [Abstract] [Full Text] [Related]

  • 11. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K, Babalola K, Wang J, Espina R, Yu L, Adedoyin A, Talaat R, Mutlib A, Scatina J.
    Chem Res Toxicol; 2009 Feb 01; 22(2):311-22. PubMed ID: 19067650
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
    Baillie TA.
    Chem Res Toxicol; 2009 Feb 01; 22(2):263-6. PubMed ID: 19216579
    [Abstract] [Full Text] [Related]

  • 14. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, Evans DC.
    Chem Res Toxicol; 2009 Feb 01; 22(2):280-93. PubMed ID: 19183054
    [Abstract] [Full Text] [Related]

  • 15. Human radiolabeled mass balance studies: objectives, utilities and limitations.
    Penner N, Klunk LJ, Prakash C.
    Biopharm Drug Dispos; 2009 May 01; 30(4):185-203. PubMed ID: 19544285
    [Abstract] [Full Text] [Related]

  • 16. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH.
    Chem Res Toxicol; 2009 Jul 01; 22(7):1217-20. PubMed ID: 19563206
    [Abstract] [Full Text] [Related]

  • 17. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
    Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, Smith DA.
    Chem Res Toxicol; 2009 Feb 01; 22(2):357-68. PubMed ID: 19146377
    [Abstract] [Full Text] [Related]

  • 18. Predicting circulating human metabolites: how good are we?
    Anderson S, Luffer-Atlas D, Knadler MP.
    Chem Res Toxicol; 2009 Feb 01; 22(2):243-56. PubMed ID: 19138063
    [Abstract] [Full Text] [Related]

  • 19. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites.
    Wang WW, Khetani SR, Krzyzewski S, Duignan DB, Obach RS.
    Drug Metab Dispos; 2010 Oct 01; 38(10):1900-5. PubMed ID: 20595376
    [Abstract] [Full Text] [Related]

  • 20. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M, Zhang D, Zhang H, Shyu WC.
    Biopharm Drug Dispos; 2009 May 01; 30(4):163-84. PubMed ID: 19544287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.